Substance Abuse, Intravenous
14
0
0
14
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
14%
2 trials in Phase 3/4
57%
8 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (14)
Break the Cycle: Prevention for Reducing Initiation Into Injection Drug Use
Non-Invasive Vagal Nerve Stimulation in Opioid Use Disorders
Change the Cycle: An RCT to Prevent Injection Initiation
The Long-Term Treatment of Drug Addiction and Unemployment
BRIDGE: Improving HIV Service Delivery for People Who Inject Drugs
Hepatitis C Treatment in PWIDs: MAT or Syringe Exchange Assisted-therapy vs Standard of Care
Counseling Conditions for Buprenorphine in a Primary Care Clinic - 1
Study of Buprenorphine Maintenance Treatment for Opioid Dependence in Primary Care
The Therapeutic Workplace Initiation Study
Employment-based Reinforcement of Naltrexone Ingestion and Abstinence
Contingency Management in the Delivery of HAART to Drug Users in Chennai, India
Conflict Between Maternal Autonomy and Child Health in Substance-use
Post-marketing Surveillance Study of Ex-intravenous Drug Abusers With Chronic Hepatitis C Treated With PegIntron Plus Rebetol (P04408/MK-4031-261)
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users